Sign In
Buy QGEN
$36.45
+0.760 (+2.13%)
At Close: Jun 03, 2026
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
10:40am, Tuesday, 29'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
04:05pm, Tuesday, 22'nd Apr 2025
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its po
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 16'th Apr 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
01:30am, Tuesday, 15'th Apr 2025
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments du
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
11:22am, Tuesday, 08'th Apr 2025
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, M
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
02:28pm, Sunday, 06'th Apr 2025
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earni
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
01:30am, Tuesday, 01'st Apr 2025
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria re
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
06:00am, Monday, 31'st Mar 2025
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statement
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
07:55am, Wednesday, 12'th Mar 2025
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
07:35am, Friday, 07'th Mar 2025
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
01:00am, Thursday, 06'th Mar 2025
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
01:00am, Monday, 03'rd Mar 2025
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringeme
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
04:39pm, Tuesday, 25'th Feb 2025
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's f
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
07:00am, Sunday, 23'rd Feb 2025
Stock splits can be undertaken for several reasons. They can bring a stock's price down to make it more affordable for a wider range of investors.
The FFPE tissue samples for genomics study & analysis market is poised for significant growth, driven by rising cancer incidence, advancements in genomic technologies, and an increasing focus on perso
